Plavix Court Fight Continues
The Great Plavix Patent Battle was scheduled to resume in federal court Monday, with Bristol-Myers Squibb(BMY Quote) and Sanofi-Aventis(SNY Quote) try to show that generic versions of the drug would cause them irreparable harm.
The two drug giants are asking a federal judge to stop the Canadian drugmaker Apotex from selling reduced-price copies of the anticoagulant. They also want the judge to order a recall of all generic Plavix that Apotex has been selling since Aug. 8. However, it's unclear how quickly the judge, Stanley H. Stein, would act on the companies' request for a preliminary injunction. Oral arguments began Friday, and a complex issue like the Plavix patent dispute doesn't lend itself to a quick decision from the bench. According to Reuters, the judge's clerk said a ruling wouldn't be issued Monday. Sanofi-Aventis holds the Plavix patent, and Bristol-Myers owns the U.S. marketing rights. They want a preliminary injunction to halt what they say is a flood of generic Plavix until a federal judge can hear their patent infringement claim against Apotex. However, a full trial probably wouldn't start until January, and a decision would likely take several months. The companies say they can't wait that long, contending that such a delay would drastically erode sales of the drug, a blood-clot preventer. Last year, Plavix contributed $3.8 billion, or 20%, of Bristol-Myers' total revenue, and $2.45 billion, or 7.4%, of Sanofi-Aventis' sales.- Loading Comments...
- Loading Comments...
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,023.42 | 1,069.30 | 2,112.44 | 35.03 |
Oil *
76.05
|
|
UP
17.46
|
UP
2.67
|
UP
7.12
|
DOWN
0.30
|
10 Yr
3.50%
SPDR Gold
107.43
|
|
+0.17%
|
+0.25%
|
+0.34%
|
-0.85%
|
Data delayed 20 minutes |














